Quality Peptides White Powder Factory Supply Weight Loss Adipotide

Name:  Lynn
Wechat：  15914422644

Tel：+86  15914422644

Whatsapp: +852 6252 8290

Email：    guangsheng 5   @zgguangsheng.com

1. Core Molecular & Physicochemical Specifications

2. Mechanism of Action

1. Targeting Module (CKGGRAKDC): This sequence specifically binds to prohibitin and annexin A2 (ANXA2) receptors, which are uniquely expressed on the endothelial cells of blood vessels supplying WAT, ensuring targeted action on fat - feeding blood vessels.
2. Pro - Apoptotic Module (D(KLAKLAK)₂): The D - enantiomer cationic peptide sequence disrupts the mitochondrial membrane potential of the targeted vascular endothelial cells, triggering the intrinsic apoptotic pathway, leading to vascular atrophy and apoptosis, cutting off the blood and oxygen supply to fat cells, and finally causing fat cell death due to ischemia.
3. Specificity: It only acts on WAT vasculature, without affecting brown adipose tissue (BAT) or other normal tissues, so it will not interfere with BAT - related thermogenesis.

3. Biological Functions & Research Applications

3.1 Core Biological Effects

• Targeted Fat Reduction: Selectively eliminates WAT by destroying its blood supply, with significant reductions in abdominal fat and overall body fat observed in animal models.
• Metabolic Improvement: Enhances insulin sensitivity, lowers blood glucose and triglyceride levels, and improves obesity - related metabolic disorders.
• Non - Hormonal Regulation: It does not interfere with the body's endocrine or metabolic pathways, acting through a unique vascular targeting mechanism different from traditional weight - loss methods such as appetite suppression or metabolism promotion.

3.2 Research Applications

4. Production & Quality Control

4.1 Manufacturing Process

1. Solid - Phase Peptide Synthesis (SPPS): Fmoc chemistry is used to assemble the two functional modules and the connecting glycine - glycine (GG) linker. High - performance reversed - phase liquid chromatography (RP - HPLC) is used for purification to reach a purity of ≥99%.
2. Lyophilization: Freeze - drying forms a stable powder, which extends the shelf - life and facilitates storage and transportation under cold - chain conditions.

4.2 Quality Testing Standards

5. Preclinical Data & Safety Profile

5.1 Preclinical Efficacy

• In rhesus monkeys, after 4 weeks of treatment, body weight decreased by 11 - 15%, abdominal fat decreased by 30 - 40%, and insulin sensitivity increased by 20 - 30%.
• In mice, it can reduce WAT mass by 40 - 50%, improve glucose tolerance, and has no significant effect on lean body mass or organ function.

5.2 Safety & Limitations

6. Administration & Handling Recommendations

6.1 Administration Routes & Research Dosage

• Subcutaneous Injection (SC): The most common route for preclinical research. For mice, the dosage is 1 - 5 mg/kg/day, administered once daily for 2 - 4 weeks. For non - human primates, the dosage is 0.5 - 2 mg/kg/day, with a treatment cycle of 3 - 4 weeks.
• Intravenous Injection (IV): Used for acute efficacy research, with a dosage of 0.3 - 1 mg/kg (single - dose or short - term multiple doses).

6.2 Handling Guidelines

• Storage: Store at - 20°C in a dry and dark environment; protect from light and moisture.
• Transport: Transport under cold - chain conditions (2 - 8°C) to ensure stability.
• Research - Only Use: High - purity powder is only for R&D purposes and not for human clinical use without regulatory approval.
• Disposal: Dispose of in accordance with local chemical waste regulations to avoid environmental pollution.

7. Advantages of High - Purity Adipotide Powder

1. Precise Targeting: High purity ensures specific binding to WAT vascular receptors, minimizing off - target effects and ensuring the reliability of experimental results.
2. Stable Activity: Low impurity content reduces the risk of degradation and maintains consistent pro - apoptotic activity during the research cycle.
3. Reproducible Data: Conforms to GMP - level quality standards, which is conducive to the repeatability and comparability of preclinical experiments.
4. Safety Assurance: High purity reduces the probability of non - specific toxic and side effects caused by impurities in animal models.